Alzheimer’s disease
Biogen and its partner Eisai Company released additional details about the Phase IV post-marketing study of the drug.
Cortexyme said it plans to provide additional updates pending further talks with the FDA.
Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”
California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
2021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
PRESS RELEASES